Cross border LSHC M&A deal volume in China 2018-2020, by target sub-sector
The number of M&A deals in the Chinese life science and healthcare (LSHC) industry rose from 24 to 37 in 2020. The biopharma sub-sector recorded a significant increase in the deal volume. However, the year was an outlier, as the M&A activity in the LSHC industry returned to pre-pandemic levels in the following year.